127 related articles for article (PubMed ID: 33594656)
41. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R
Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436
[TBL] [Abstract][Full Text] [Related]
42. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
[TBL] [Abstract][Full Text] [Related]
43. Increased body mass index is associated with improved overall survival in extranodal natural killer/T-cell lymphoma, nasal type.
Li YJ; Yi PY; Li JW; Liu XL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Yao Y; Fan Z; Tang T; Jiang WQ
Oncotarget; 2017 Jan; 8(3):4245-4256. PubMed ID: 28002803
[TBL] [Abstract][Full Text] [Related]
44. Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma.
Wang L; Wang H; Xia ZJ; Huang HQ; Jiang WQ; Lin TY; Lu Y
Ann Hematol; 2015 Oct; 94(10):1645-54. PubMed ID: 26082333
[TBL] [Abstract][Full Text] [Related]
45. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Gómez J; Millá F; Feliu E
Haematologica; 1998 Jun; 83(6):508-13. PubMed ID: 9676023
[TBL] [Abstract][Full Text] [Related]
46. Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: a retrospective study.
Yang M; Ping L; Liu W; Xie Y; Aliya ; Liu Y; Nuersulitan R; Zhu J; Wu M; Song Y
Hematology; 2019 Dec; 24(1):413-419. PubMed ID: 30922173
[TBL] [Abstract][Full Text] [Related]
47. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database.
Castillo JJ; Winer ES; Olszewski AJ
Cancer; 2013 Oct; 119(20):3672-9. PubMed ID: 23913575
[TBL] [Abstract][Full Text] [Related]
48. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
Fayad L; Thomas D; Romaguera J
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
[TBL] [Abstract][Full Text] [Related]
49. Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi.
Stanley CC; Westmoreland KD; Heimlich BJ; El-Mallawany NK; Wasswa P; Mtete I; Butia M; Itimu S; Chasela M; Mtunda M; Chikasema M; Makwakwa V; Kaimila B; Kasonkanji E; Chimzimu F; Kampani C; Dhungel BM; Krysiak R; Montgomery ND; Fedoriw Y; Rosenberg NE; Liomba NG; Gopal S
Br J Haematol; 2016 Jun; 173(5):705-12. PubMed ID: 26914979
[TBL] [Abstract][Full Text] [Related]
50. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors.
Reiser M; Josting A; Soltani M; Staib P; Salzberger B; Diehl V; Engert A
Leuk Lymphoma; 2002 Apr; 43(4):805-11. PubMed ID: 12153168
[TBL] [Abstract][Full Text] [Related]
51. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation.
Alderuccio JP; Zhao W; Desai A; Ramdial J; Gallastegui N; Kimble E; de la Fuente MI; Husnain M; Rosenblatt JD; Alencar AJ; Schatz JH; Moskowitz CH; Chapman JR; Vega F; Reis IM; Lossos IS
Am J Hematol; 2019 May; 94(5):585-596. PubMed ID: 30784098
[TBL] [Abstract][Full Text] [Related]
52. [Analysis on Clinical Characteristics and Prognosis of 47 Patients with Extranodal NK/T Cell Lymphoma].
Li QH; Yang P; Wang JJ; Dong F; Tian L; Wan W; Ke XY; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):86-90. PubMed ID: 33554802
[TBL] [Abstract][Full Text] [Related]
53. AIDS-related sinonasal Burkitt lymphoma successfully treated with intensive chemotherapy regimen and high active antiretroviral therapy.
Werutsky G; de Carvalho GP; da Silva VD; Garicochea B
Hematol Oncol Stem Cell Ther; 2011; 4(1):41-4. PubMed ID: 21460606
[TBL] [Abstract][Full Text] [Related]
54. [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy].
Zhang MC; Xu PP; Zhong HJ; Zhao X; Zhao WL; Cheng S
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):772-777. PubMed ID: 29081194
[No Abstract] [Full Text] [Related]
55. Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4.
Zhen Z; Zhu J; Wang J; Lu S; Sun F; Huang J; Sun X
Pediatr Hematol Oncol; 2020 Sep; 37(6):489-499. PubMed ID: 32364412
[TBL] [Abstract][Full Text] [Related]
56. Treatment Strategies and Prognostic Factors of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Multicenter Study of 272 Cases from the China Lymphoma Patient Registry.
Yang H; Wu M; Shen Y; Lei T; Mi L; Leng X; Ping L; Xie Y; Song Y; Cen X; Zhu J
Int J Med Sci; 2019; 16(7):1023-1031. PubMed ID: 31341416
[No Abstract] [Full Text] [Related]
57. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
[TBL] [Abstract][Full Text] [Related]
59. [Clinical Efficacy and Prognostic Factors of Newly Diagnosed Children[JP] with Burkitt Lymphoma Treated by High-Dose and Short-Course Modified LMB Regimen ± Rituximab].
Wang BT; Dang HB; Wei YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):529-534. PubMed ID: 32319391
[TBL] [Abstract][Full Text] [Related]
60. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
